Fortnightly Review

Acute circulatory support

Matthew J Barnard, Stephen P K Linter

Numerous drugs can increase cardiac output, thereby improving tissue oxygen delivery, but often they do this at the expense of increasing myocardial oxygen demand. This may be critical when cardiac function is substantially impaired or ischaemia is the precipitating cause. Using polypharmacy to substantially improve cardiovascular status requires detailed knowledge of the pharmacodynamics and interactions of the available agents so that they may be tailored to the individual patient. In some settings combinations of inotropes and vasodilators may be desirable to minimise cardiac workload. In other instances vasopressors may be necessary to urgently restore a minimum perfusion pressure. This paper reviews the use of this group of drugs as well as the mechanical assist devices that may be used when drugs fail.

The management of acute heart failure and the ensuing low cardiac output state remains a fundamental challenge in cardiac intensive care. When oxygen delivery declines tissue requirements are initially maintained by an increased oxygen extraction. However, below a critical level of delivery consumption falls (supply dependency) and anaerobic metabolism and lactate production ensue. Multiple organ failure develops if cardiac function is inadequate for an appreciable period.

Treatment is aimed at increasing cardiac output and tissue oxygen delivery to a viable level, thus restoring vital organ function. Packed cell volume, heart rate, and fluid management should be optimised with invasive monitoring techniques. Positive pressure ventilation may improve oxygenation, reduce oxygen demands, and decrease left ventricular afterload. Reducing afterload with vasodilators increases cardiac output, but this approach is often limited by hypotension. Pharmacological enhancement of contractility and mechanical augmentation of stroke volume are the final means of treating acute heart failure. We review the non-digitalis positive inotropic drugs and temporary mechanical pumps that are useful for this purpose.

Catecholamines

Catecholamines retain a primary position in the treatment of acute heart failure by virtue of their pharmacokinetic properties, predictable pharmacodynamic responses, and wide range of haemodynamic effects. The half life of most agents is two to three minutes, ensuring that steady state infusion concentrations are reached within 10 to 15 minutes. Infusion rates are linearly related to plasma concentrations, which are directly related to pharmacodynamic effects.

The haemodynamic effects are predictable from a knowledge of their activity at autonomic receptors (see table).

Activity of catecholamines at adrenergic receptors

<table>
<thead>
<tr>
<th>Dopamine</th>
<th>Dose</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dopaexamine</td>
<td>++</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>Dopamine</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Dobutamine</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Noradrenaline</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Adrenaline</td>
<td>0</td>
<td>0</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Isoprenaline</td>
<td>0</td>
<td>0</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

0 = No agonism. + = Mild agonism. +++ = Moderate agonism. ++++ = Pronounced agonism.

Response to catecholamine infusions may be limited by the reduction in β receptor density and function (down regulation) which occurs with chronic sympathetic stimulation. The defect in β receptor responses has been attributed to a 30% increase in activity of the inhibitory form of the G regulatory protein acting on adenyl cyclase.

DOPAMINE

Dopamine is a naturally occurring sympathetic amine which is the endogenous precursor of noradrenaline. At low doses (<4 μg/kg/min) dopamine predominantly activates dopamine 1 and dopamine 2 receptors, increasing renal plasma flow, the glomerular filtration rate, and sodium excretion. β1 Receptors are stimulated at doses between 4 and 10 μg/kg/min, resulting in an increased heart rate and cardiac output. At doses greater than 10 μg/kg/min α receptor activation leads to vasoconstriction and raised systemic and ventricular filling pressures, which may result in ischaemia. Dopamine is often used as the first choice for treating shock as it increases inotropy while also restoring perfusion pressure to vital organs. It is useful in low dosage for augmenting renal blood flow, particularly in combination with other agents. Dopamine may preserve renal function in shock states when noradrenaline has been used to raise systemic pressure.

DOBUTAMINE

Dobutamine is a synthetic catecholamine with pronounced β1 agonist effects and weak β2 effects. We now know it to be a racemic mixture of laevo and dextro isomers which differ in adrenergic receptor affinities. The laevo isomer is predominantly an α agonist, whereas the dextro isomer is a potent β1 and β2 agonist. Dobutamine increases contractility via its β effects, thus raising cardiac output, stroke volume, and (at higher doses) heart rate. Peripheral vasodilatation is well demonstrated by an increase in cardiac output.
When the drug is given to animals with artificial hearts. Diastolic filling pressures are lowered and left ventricular wall tension and cavity size decline.

Dobutamine improves ventricular perfusion without exagerating myocardial injury in patients after infarction and decreases infarct size in animal coronary ligation models. The consensus of several animal and human studies is that overall dobutamine improves the myocardial oxygen supply and demand balance if tachycardia is avoided.

ADRENALINE

Adrenaline is an endogenous catecholamine secreted by the adrenal medulla. It is a very potent \( \alpha \) and \( \beta_1 \) agonist and moderate \( \beta_2 \) agonist. \( \beta \) Effects predominate at doses of between 0.04 and 0.1 \( \mu \)g/kg/min, resulting in increased heart rate and contractility with an unchanged or lowered total peripheral resistance. At higher doses \( \alpha \) effects prevail, resulting in raised peripheral resistance and blood pressure. Although it dilates myocardial arterioles and venules, the increases in rate, contractility, and vascular resistance may result in myocardial ischaemia. Concomitant treatment with a vasodilator may counteract the \( \alpha \) mediated vasoconstriction, thus improving the myocardial oxygen supply to demand ratio. Adrenaline may increase coronary perfusion pressure in a shocked patient with a low diastolic blood pressure, thus ameliorating myocardial ischaemia.

Adrenaline's usefulness relates to its greater maximal effects (efficacy) than other \( \beta \) agonists. It is indicated in patients who do not respond to dobutamine or dopamine and in patients with life threatening hypotension. Its efficacy combined with useful bronchodilatory effects makes it the drug of choice in anaphylaxis.

NORADRENALINE

Noradrenaline is an endogenous catecholamine secreted by the adrenal medulla. It is the main neurotransmitter at sympathetic postganglionic fibres. It is a potent \( \beta_1 \) agonist and very potent \( \alpha_1 \) and \( \alpha_2 \) agonist. Administration of noradrenaline leads to a rise in contractility (mediated by \( \alpha_1 \) receptors) and a substantial increase in systemic vascular resistance, which may decrease cardiac output. Blood pressure increases and heart rate may decline via baroreceptor mediated reflexes. Myocardial oxygen consumption is increased, and noradrenaline may exacerbate ischaemia and compromise ventricular function. Simultaneous treatment with a vasodilator may counteract the rise in vascular resistance, resulting in a net increase in contractility alone. Pulmonary vascular resistance is increased by noradrenaline. However, its use has been paradoxically advocated in severe right ventricular failure. Epoprostenol infusion into the right atrium and noradrenaline infusion into the left atrium lowered pulmonary but not systemic vascular resistance.

Noradrenaline is used in settings where the importance of increasing perfusion pressure outweighs the disadvantages of lowering cardiac output, or to counterbalance vasodilatory effects of other agents.

ISOPRENALEine

Isoprenaline is a synthetic catecholamine with the most potent direct \( \beta_1 \) and \( \beta_2 \) agonist effects and no \( \alpha \) effects. Administration results in improved contractility and a pronounced increase in heart rate and cardiac output. Systemic vascular resistance is reduced, resulting in a decline in systemic and diastolic blood pressure. Undesirable effects include tachycardia, a propensity towards arrhythmias, and a diversion of blood flow from vital organs to muscle and skin. Isoprenaline can reduce the myocardial oxygen supply to demand ratio and may produce coronary steal. Isoprenaline is useful in patients with bradycardia and atrioventricular block, particularly in denervated hearts. It may, however, worsen Mobitz type II block. Pulmonary vasodilatory effects make it useful in the treatment of pulmonary hypertension and right ventricular failure, particularly in patients with cardiac transplants. Isoprenaline decreases carotid and coronary blood flow during resuscitation from cardiac arrest, when it should be used with caution.

DOPEXAMINE

Dopexamine is a synthetic catecholamine with pronounced \( \beta_2 \) agonism (60 times as potent as dopamine), negligible \( \beta_1 \) agonism, no \( \alpha \) effects, significant dopamine 1 receptor activation (one third the potency of dopamine), and mild dopamine 2 receptor activation. In addition, it is a potent reuptake inhibitor of neurally released catecholamines.

Cardiovascular responses to dopexamine infusion include increased heart rate and cardiac index. The increase in left ventricular contractility is less than that evoked by dobutamine, but there is a greater decline in systemic and pulmonary vascular resistance. Diastolic filling pressures fall and mean arterial pressure usually changes by less than 10%. Dopexamine augments renal blood flow with one third the potency of dopamine, but this effect declines at doses over 2 \( \mu \)g/kg/min. Possibly the dopamine 1 receptor mediated natriuretic effects are opposed by a tubular \( \beta_2 \) agonist effect. Dopexamine decreases the incidence of postoperative renal failure in orthotopic liver transplant recipients. Other benefits of dopexamine include an increase in hepatosplanchnic blood flow. This has aroused interest because of an appreciation of the importance of splanchnic vasoconstriction and ischaemia in the pathogenesis of multiorgan failure. Dopexamine increases oxygen delivery and consumption and decreases plasma lactate concentrations when combined with noradrenaline in patients with septic shock.

Overall dopexamine should be regarded as an inodilator with haemodynamic effects similar to those of the phosphodiesterase inhibitors. It is used as an alternative to dobutamine to increase cardiac output and produce vasodilatation, particularly in the renal and mesenteric beds.

Newer agents

The search for inotropic drugs which enhance systemic flow and provide some degree of renal protection but lack undesirable vasoconstrictor effects has led to the development of several novel dopaminergic agents. Fenoldopam is a dopamine 1 receptor agonist with no \( \alpha \) or \( \beta \) effects. It is 10 times more potent than dopamine at dopamine 1 receptors. It increases the cardiac index and produces dose dependent reductions in systemic vascular resistance and blood pressure. Renal blood flow increases by 40%. Ibopamine is a compound which is metabolised to epinephrine, a dopamine 1 receptor agonist with some activity at \( \alpha \) and \( \beta \) receptors. Overall it is a vasodilating mild positive inotrope.

Orally effective sympathomimetic drugs include terbutaline, pirbuterol, pronateral, TA-064, butopamine, ibopamine, and dopexamine. They have no current place in the treatment of acute heart failure.

Colforsin directly stimulates sarcoclemmal adenylate cyclase and is a moderate inotrope and vasodilator. Investigations are being carried out into agents such as MCI-154 which sensitise the contractile apparatus to calcium.
**Phosphodiesterase inhibitors**

The phosphodiesterase inhibitors are a group of potent inotropic and vasodilating agents, often referred to as inodilators. There are three groups of phosphodiesterase inhibitors: the bipyridine inhibitors amrinone and milrinone; the imidazole derivatives enoximone and piroximone; and the benzimidazole derivatives sulmazole, pimobendan, and adibendan.

These agents selectively and competitively inhibit cyclic nucleotide phosphodiesterase F III in cardiac and vascular smooth muscle. This enzyme exists in two isoforms, of which enoximone inhibits only the cyclic guanosine monophosphate sensitive form. A rise in the intracellular concentration of cyclic adenosine monophosphate seems to be the important mechanism mediating positive inotropy, though this remains controversial. Phosphodiesterase inhibitors produce no alteration in calcium sensitivity as assayed in chemically skinned myofibrils.

Phosphodiesterase inhibitors increase stroke volume and cardiac output by increasing inotropy while decreasing systemic and pulmonary vascular resistance, without altering heart rate. The decrease in impedance to left ventricular ejection and the rise in contractility lower myocardial wall tension, oxygen consumption, and diastolic filling pressures. Phosphodiesterase inhibitors have a unique beneficial effect on the diastolic properties of the left ventricle, as manifested by improved relaxation, compliance, and filling. An improvement in relaxation (lusitropy), as regulated by load, inactivation, and non-uniformity, is achieved at lower doses than those necessary for inotropic effects.

The inotropic effects of the phosphodiesterase inhibitors have been challenged with suggestions that the improvements in cardiac performance are attributable to vasodilatation alone. However, there is now ample evidence for an independent positive inotropic effect. Analysis of effects on the pressure-volume relation shows that phosphodiesterase inhibitors are useful in right heart failure. They can increase cardiac index by 30% while decreasing mean pulmonary artery pressure by 10% and pulmonary vascular resistance by 40%. Others have recorded similar effects in patients with mitral stenosis and in those with previously unresponsive pulmonary hypertension.

At high doses substantial reductions in mean arterial pressure may occur. This effect may be minimised by volume expansion, slower administration of loading doses, and giving vasopressors such as noradrenaline. Nevertheless, enoximone has been used successfully in shock.

The benzimidazole derivatives combine phosphodiesterase inhibition with calcium sensitising properties.

Development of the phosphodiesterase inhibitors has effectively been halted by evidence of adverse effects of sulmazole, pimobendan, and adibendan. Oral administration of milrinone to patients with chronic heart failure worsened symptoms and increased mortality by 30%. Smaller studies with milrinone and amrinone yielded similar results. This report raises important points concerning the treatment of severe heart failure. Investigations in rats showing improved survival are attributable to exclusive peripheral vasodilatation without positive inotropy. The benefit of manipulating myocardial energetics in the failing heart is now being questioned. Cyclic adenosine monophosphate concentrations are depleted in patients with incapacitating ventricular failure, but this may be a protective mechanism.

Despite these considerations most authorities consider that there is no evidence that short term intravenous infusions of phosphodiesterase inhibitors worsen mortality in acute heart failure. We believe, however, that long term follow up of patients who have been given short term infusions is warranted before they can be recommended without reservation.

Amrinone is a bipyridine with an elimination half life of greater than two hours. Electrophysiological study shows a decrease in the atrial and atrioventricular functional refractory period. Side effects of oral amrinone limit its usefulness and include arrhythmias, thrombocytopenia, gastrointestinal disturbances, and liver function abnormalities.

Milrinone is a second generation bipyridine derivative of amrinone and is 15 times more potent than amrinone. It increases renal and splanchnic blood flow. Its half life is two hours; side effects include fluid retention and arrhythmias at high doses.

Enoximone is an imidazole with an elimination half life of four hours. It is metabolised by sulphotisation to a substance with inotropic and vasodilatory properties and metabolised with 0-14 times the potency and 13 times the duration of the parent compound.

Phosphodiesterase inhibitors significantly improve the cardiac index and have favourable effects on diastolic filling pressures, isovolumic relaxation, myocardial oxygen consumption, and pulmonary vascular resistance, usually without causing tachycardia or receptor down regulation. We recommend them as first line agents in patients with adequate filling pressures and without pre-existing severe vasodilatation. Simultaneous administration of vasocostrictors may be necessary to avoid hypotension. The effects of phosphodiesterase inhibitors and catecholamines are additive and synergistic. Infusions of amrinone with noradrenaline, dopamine, and dobutamine have all shown improved perfusion and attenuation of the vasocostrictive effects of the adrenergic agents.

**Pharmacological strategy**

Recently the classification of shock states has altered from a division into aetiological groups such as cardiogenic, hypovolaemic, and septic to an emphasis on pathophysiological alterations in oxygen delivery and utilisation. Similarly, the selection of appropriate agents for clinical settings is dictated by individual haemodynamic derangements rather than by the specific diagnosis. This requires assessment variously of heart rate, systemic and pulmonary arterial pressures, filling pressures, cardiac output, vascular resistances, and stroke work.

Pharmacological treatment, however, is affected by the importance of myocardial ischaemia. In ischaemia the end systolic pressure volume line is shifted to the right (decreased ejection) and the end diastolic line is shifted to the left (decreased filling) (fig 1). Sympathomimetics will restore both of these indices at the possible expense of increased myocardial oxygen requirement and decreased supply owing to tachycardia. After myocardial infarction or cardiac surgery we use a three step approach. Vasodilators are the first
Intra-aortic balloon counterpulsation

The concept of counterpulsation was first advanced in 1958, and Kantrowitz et al reported clinical success with the intra-aortic balloon pump in 1968. A balloon is positioned in the descending aorta, just distal to the left subclavian artery, and inflated with 50 ml carbon dioxide or helium at the onset of diastole. This results in displacement of blood into the proximal and distal aorta, increasing diastolic arterial pressures. Rapid deflation before systole decreases aortic pressures and reduces the impedance to left ventricular ejection, thus unloading the left ventricle. Diastolic augmentation of blood flow increases cardiac output (by some 20-50%); coronary, cerebral, and renal perfusion; left ventricular stroke work index; and ejection fraction. Systolic arterial pressure, left ventricular wall tension, and end diastolic filling pressure and volume decline. Myocardial oxygen supply increases while demand decreases. The intra-aortic balloon pump ameliorates myocardial ischaemia, increases watershed perfusion in acute myocardial infarction, and possibly decreases infarct size.

Box A outlines the indications for intra-aortic balloon pump placement. Insertion usually occurs via the femoral artery and may be percutaneous or surgical. Balloon inflation may be triggered from the R wave of the electrocardiogram (to coincide with the peak of the T wave), from an arterial trace, or at an intrinsic set rate. Balloon inflation should occur at closure of the aortic valve—that is, at the dicrotic notch. Premature inflation will increase impedance to left ventricular ejection. Delay in inflation will needlessly decrease diastolic augmentation. Automatic adjustment of inflation has been described.

Complications with intra-aortic balloon pumps are frequent and may be severe. Up to 36% of patients may suffer vascular complications. Leg ischaemia is the most common and may require removal of the balloon and embolectomy. A greater incidence occurs in patients with diabetes, in peripheral vascular disease, and in women and possibly with percutaneous insertion. Arterial injury and aortic dissection occur in fewer than 5% of cases, though necropsy studies indicate that many instances of aortic dissection are not clinically recognised. Preventing thromboembolisation requires full anticoagulation and avoidance of balloon non-inflation. Thrombocytopenia and haemolysis may occur, and infectious complications are manifested in 1-3% of patients.

Ventricular assist devices

The intra-aortic balloon pump will not be effective in patients with a cardiac index below 1.4 l/min. These patients may benefit from one of the mechanical pumps designed for short term use—the ventricular assist devices. These pumps have evolved directly from heart-lung bypass machines developed for cardiac surgery. They may be classified in several ways (box B).

Patient selection is the most important determinant of a successful outcome. Indications for insertion of a ventricular assist device include failure to wean from cardiopulmonary bypass, cardiogenic shock after infarction or myocarditis, as a bridge to transplantation, and cardiac allograft failure. Clinical criteria for insertion of a ventricular assist device at this hospital are listed in box C and are similar to those used elsewhere.

Absolute contraindications to ventricular assist devices include multiorgan failure, septic shock, and irreversible brain damage. Relative contraindications include cardiopulmonary bypass longer than five hours, age over 70, coagulopathy, renal failure, and localised infection.

Box A
Indications for intra-aortic balloon pump insertion
- Perioperative insertion in cardiac surgery
- High risk patients with severe ventricular dysfunction
- Refractory angina
- Aneurysmectomy
- Facilitation of separation from cardiopulmonary bypass
- Donor dysfunction after cardiac transplantation
- Ischaemia
- Refractory angina
- Myocardial infarction with cardiogenic shock
- Ventricular septal defect after infarction
- Papillary muscle dysfunction or rupture
- Prophylaxis in high risk patients
- Angioplasty
- Preoperatively in patients with severe ventricular dysfunction

Box B
Mechanical circulatory support
- Flow
- Pulsatil
- Non-pulsatile
- Drive source
- Pneumatic
- Electromechanical
- Anatomy
- Left heart assist
- Right heart assist
- Biventricular assist
- Position
- Intracorporeal
- Paracorporeal
- Extracorporeal
- Heterotopic
- Orthotopic
- (total artificial heart)
The Abiomed BVS 5000, a biventricular support system, is the device most often used at this hospital (fig 2). It is a gravity filled, pneumatically driven, external prosthetic ventricle with an electromechanical console. Gravity filling allows the ventricular rate to adjust to venous return, in a fill to empty mode, avoiding pulmonary-systemic imbalance when providing biventricular assist. The Abiomed was the first device to receive approval from the United States Food and Drug Administration for postcardiotomy ventricular dysfunction. Of 347 patients given support with this device, 93 survived to hospital discharge.

The Biomedicus Centrifugal Pump is an external vortex device providing non-pulsatile flow, utilising an electrically powered magnetic impeller. It is easy to apply, relatively cheap, and can provide high flow rates. Non-pulsatile pumps are rarely used for longer than one to two weeks, usually after cardiotomy. A degree of success (31% survival greater than 30 days) was reported in 67 patients after placement in an emergency or cardiac arrest setting.

The Thoratec Pierce Donachy ventricular assist device is a paracorporeal pulsatile sac-type pump. The pumps lie on the abdominal wall. The Novacor device is an intracorporeal left ventricular assist device consisting of a one piece polyurethane sac and a pair of pusher plates. The pump is placed in front of the posterior rectus sheath. The Thermocardiostems ventricular assist device is a pneumatically activated pusher plate intracorporeal pump. The device is placed between the left ventricular apex and ascending aorta.

ASSIST-DEVICES AND ARTIFICIAL HEARTS REGISTRY

A combined registry for the clinical use of ventricular assist devices and total artificial hearts was established in 1985. A recent report contained data on over 1500 patients. Support was instituted for postcardiotomy cardiogenic shock in 965 patients, 433 (45%) of whom were weaned from support, but only 237 (25%) survived to hospital discharge. A total of 544 patients received circulatory support in conjunction with heart transplantation, of whom 189 received a total artificial heart. Of the patients allocated to receive transplants, 436 required support for haemodynamic deterioration before orthotopic transplantation and 108 were supported after transplantation. Only 328 (69%) patients supported before operation were actually given a transplant, of whom 217 (66%) survived to discharge. The Kaplan-Meier survival rate at two years in this group was 65%, which compares with 80% in patients given transplants who were not receiving mechanical support. However, the two year survival for patients requiring only univentricular support was 83%. The incidence of multiorgan failure was substantially higher in patients bridged with a total artificial heart.

Several reports have described small series of

**Box C**

**Criteria for ventricular assist device insertion**

- Maximal pharmacological support
- Volume replacement
- Intra-aortic balloon pump
- Cardiac index < 1.8 l/min/m²
- Left atrial pressure > 20 mm Hg
- Central venous pressure > 20 mm Hg
- Oliguria
- Mixed venous saturation < 60%
- Worsening acidosis
- Pulmonary insufficiency

![fig 2—Abiomed biventricular support system. Top: Patient connected to system. Middle: Enlarged view of pneumatic pumps. Left pump contains oxygenated blood. Bottom: Cannula insertion sites under costal margin](image-url)
patients supported with ventricular assist devices for one to 150 days with varying success.16-47 Critics claim that mechanical support as a bridge to transplantation results in donor organs being offered to those most critically ill and thus with the worst chance of success. However, as experience with devices increases, survival rates continue to improve and are approaching those achieved after transplantation without mechanical support.16-47 There are enthusiastic calls for increased and earlier insertion of devices.48-70

Ventricular assist devices are usually implanted while the patient is receiving cardiopulmonary bypass. Anticoagulation regimens vary widely.71-73 Most centres give heparin to achieve an activated clotting time of 150-200 seconds. However, numerous different regimens have been advocated, including aspirin, warfarin, dipyridamole, protease inhibitors, and protacycin analogues.52 Bleeding is a primary complication of the technique. Experience with heparin bonded tubing avoiding systemic anticoagulation has not been successful.74 The other main complications are thromboembolism, infections, mediastinitis, haemolysis, antibody development, and neurological deficits.16-47

The incidence of infection is high and is the usual cause of death. This has focused attention on completely implantable devices, and probably advances in bioengineering and biocompatibility will lead to the introduction of such devices over the next decade. A fully implantable left sided assist device developed by Novacor has reached clinical trials in the United States.75

The use of total artificial hearts has declined since 1989 (not entirely for clinical reasons) and is reviewed elsewhere.76 Thus far it has proved impossible to overcome the overwhelming infection which develops when the total artificial heart is implanted with the intention of it being a permanent device. However, outcome in patients bridged to transplantation with a total artificial heart is acceptable and compares with that in patients supported by ventricular assist devices.77

An interesting philosophy is exhibited by the St Louis group, which does not believe that outcome is improved by early transplantation after device insertion. Rather the group advocates weaning the patient from all other forms of support and then instituting a period of mobilisation and nutritional reinstatement. This approach is possible with implantable devices, and in this way patients present for transplantation in optimal condition. Aggressive mobilisation resulted in 26 of 32 patients sitting in a chair, 23 becoming mobile, and 21 using an exercise bicycle.78 Twenty one of the 23 patients were ultimately discharged. The same group reported maintenance of a patient with a Symbion total artificial heart for 440 days. There is now evidence that earlier insertion of a ventricular assist device may actually improve outcome,16-47 and a reappraisal and broadening of the criteria for mechanical support has been advocated.79

Conclusions

There are various pharmacological and mechanical strategies for restoring vital organ perfusion. The best results are obtained when interventions are directed towards the specific haemodynamic derangements of individual patients, as detected by invasive monitoring. Furthermore, repeated evaluation of the response to treatment is necessary for the appropriate commitment of intensive care resources. Acute circulatory support presupposes that a re-establishment of cardiac function is likely, either by recovery or by surgical repair or transplantation.

Structural adjustment: the wrong prescription for Africa?

Dorothy E Logie, Jessica Woodroffe

It is the privilege of the rich to watch catastrophes from a balcony. Cyprian

As Africa emerges from the “lost decade” of the 1980s it seems to be plunged into an even deeper quagmire of debt, ecological devastation, drought, and disease. Meanwhile we in the North watch the catastrophe, safe on our balconies, apparently unaware that our actions, and those of the institutions who represent us, are a major contributing factor to the continent’s downward spiral of economic and social decline.

For years we have failed the ordinary people of Africa. Cast in the popular imagination of a bottomless pit for Western charity, the reality is that Africa, despite its increasing poverty, now transfers to the rich North the debt interest. Africa is not a lost cause: the people of Africa have shown resilience with a number of vibrant and innovative community-based initiatives, and small enterprises; they have struggled tenaciously to maintain their standards of living in the face of disasters. Africa can recover. What is required is urgent debt relief, fairer terms of trade, more democratic and transparent government, and economic programs which are designed by and for African people rather than the rich in the North.

Malnutrition claims the lives of 11 000 children each day, and exposure to disease is heightened by the fact that two thirds of all Africans do not have access to clean water for cooking and drinking. Sub-Saharan African countries are currently spending 50% more on servicing their debt than on the health and education of their children and less on health per capita than they did in 1980. As Africa’s creditors, we should find this weighing heavily on our consciences. Despite paying out more than $1300 billion between 1982 and 1990, debtor countries are now 61% more indebted than they were in 1982.

How structural adjustment policies came about

The story of Africa has not always been one of doom and gloom. During the 1960s and 1970s progress in education and health care was impressive. African governments consistently allocated a higher share of their gross national product to education and health than any other developing region except the Arab states. The population with primary education doubled from 36% in 1960 to 79% in 1980. From a meagre total of 1000 university graduates in 1960, Africa was producing 70 600 graduates in 1990. Similar progress was made in health care, control of infectious diseases, hospitals, rural clinics, and community trained health workers. Child mortality more than halved in 1960 and 1990 (an achievement which took more than a century in the industrial world). The continent rode on a wave of hope.